Synthetic DNA manufacturer Twist Bioscience files for an $86 million IPO
Twist Bioscience, which manufactures synthetic genes and other DNA-based products, filed on Wednesday with the SEC to raise up to $86 million in an initial public offering.
The San Francisco, CA-based company was founded in 2013 and booked $20 million in revenue for the 12 months ended June 30, 2018. It plans to list on the Nasdaq under the symbol TWST. Twist Bioscience filed confidentially on February 8, 2018. J.P. Morgan and Cowen are the joint bookrunners on the deal. No pricing terms were disclosed.
The article Synthetic DNA manufacturer Twist Bioscience files for an $86 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.